alanine has been researched along with cobicistat in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 31 (59.62) | 24.3611 |
| 2020's | 21 (40.38) | 2.80 |
| Authors | Studies |
|---|---|
| Lepist, EI; Maclennan, K; Murray, B; Phan, TK; Ray, AS; Roy, A; Tong, L | 1 |
| Baeten, JM; Wyatt, C | 1 |
| Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
| Bam, RA; Birkus, G; Cihlar, T; Frey, CR; Stray, KM; Tsai, L; Willkom, M; Yant, SR | 1 |
| Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L | 1 |
| Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD | 1 |
| Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S | 1 |
| Deeks, ED; Greig, SL | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L | 1 |
| Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA | 1 |
| Ikushima, I; Irie, S; Ishikawa, T; Nemoto, T; Ninomiya, N; Yamada, H | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G | 1 |
| DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
| Clotet, B; Negredo, E | 1 |
| Deeks, ED | 1 |
| Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N | 1 |
| Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
| Baugh, B; Crauwels, HM; Hijzen, A; Opsomer, M; Van Landuyt, E; Vanveggel, S | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E | 1 |
| Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM | 1 |
| Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G | 1 |
| Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
| Kaplun, O; Psevdos, G | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A | 1 |
| Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
| Castagna, A; Gianotti, N | 1 |
| Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y | 1 |
| Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S | 1 |
| Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N | 1 |
| Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
| Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
| Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC | 1 |
| Emanuela, C; Francesco, L; Giorgia, G; Pasquale, N; Roberto, P; Sara, D | 1 |
| DeMarais, P; Max, B | 1 |
| Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A | 1 |
| Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
| Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
| Baugh, B; De Meyer, S; Ghys, A; Jezorwski, J; Lathouwers, E; Mohsine, EG; Van Landuyt, E; Weinsteiger, S | 1 |
| Castagna, A; Esser, S; Haubrich, R; Llibre, JM; Margot, N; McNicholl, IR; Molina, JM; Perez-Valero, I; Piontkowsky, D; Pulido, F; Shao, Y; Temme, L | 1 |
| Baugh, B; Brown, K; El Ghazi, M; Huhn, GD; Jezorwski, J; Lathouwers, E; Mussini, C; Spinner, CD; Van Landuyt, E; Wilkin, A | 1 |
| Dunn, K; Hardy, H; Kassam, PT; Luo, D; Rogers, R; Seyedkazemi, S; Sheng, S; Simonson, RB | 1 |
| Chao, CM; Hsueh, PR; Lai, CC | 1 |
| Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
| Adler, JM; Ambiel, I; Bartenschlager, R; Boulant, S; Bushe, J; Chlanda, P; Cortese, M; Diaz, RS; Fackler, OT; Fares, M; Fathy, M; Gallucci, L; Gruber, AD; Laketa, V; Lucic, B; Lusic, M; Neufeldt, CJ; Savarino, A; Shytaj, IL; Sobhy, MH; Stanifer, ML; Stolp, B; Sutton, RE; Taha Ayoub, A; Tolba, MM; Trimpert, J; Xing, N; Zhao, M; Zimmermann, L | 1 |
| Bossolasco, S; Bruzzesi, E; Carini, E; Castagna, A; Chiurlo, M; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Mastrangelo, A; Nozza, S; Poli, A; Ranzenigo, M; Spagnuolo, V; Termini, R | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ | 1 |
8 review(s) available for alanine and cobicistat
| Article | Year |
|---|---|
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration | 2019 |
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Drug Combinations; Humans; Kidney; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ritonavir | 2020 |
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine | 2021 |
19 trial(s) available for alanine and cobicistat
| Article | Year |
|---|---|
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome | 2016 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load | 2016 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States | 2017 |
Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
Topics: Adenine; Administration, Oral; Adult; Alanine; Anti-HIV Agents; Asian People; Breakfast; Cobicistat; Cross-Over Studies; Dietary Proteins; Dietary Supplements; Emtricitabine; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Quinolones; Tenofovir | 2018 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Topics: Adenine; Adult; Alanine; Area Under Curve; Biological Availability; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Fasting; Female; Food; Humans; Male; Middle Aged; Tablets; Tenofovir; Therapeutic Equivalency; Young Adult | 2019 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir | 2020 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Sequence Analysis, DNA; Tablets; Tenofovir; Viral Load | 2021 |
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Tablets; Tenofovir | 2020 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry | 2023 |
25 other study(ies) available for alanine and cobicistat
| Article | Year |
|---|---|
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.
Topics: Adenine; Alanine; Caco-2 Cells; Carbamates; Cobicistat; HIV Protease Inhibitors; Humans; Intestinal Absorption; Tenofovir; Thiazoles | 2012 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.
Topics: Adenine; Alanine; Anti-HIV Agents; Biotransformation; Carboxylic Ester Hydrolases; Cathepsin A; CD4-Positive T-Lymphocytes; Cobicistat; Drug Interactions; Gene Expression; HEK293 Cells; HeLa Cells; HIV-1; Host-Pathogen Interactions; Humans; Oligopeptides; Primary Cell Culture; Prodrugs; Proline; RNA, Small Interfering; Serine Proteinase Inhibitors; Tenofovir | 2016 |
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin | 2019 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir | 2019 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult | 2019 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States | 2019 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir | 2020 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain | 2021 |
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Prospective Studies; Tenofovir | 2021 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Topics: Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Tenofovir; Young Adult | 2021 |
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
Topics: Adolescent; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Viral Load | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cobicistat; COVID-19 Drug Treatment; Cricetinae; Disease Progression; Hepatitis C, Chronic; Humans; Mesocricetus; Pandemics; SARS-CoV-2; Viral Load | 2022 |
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |